Theravance Biopharma
TBPH
92 hedge funds and large institutions have $900M invested in Theravance Biopharma in 2019 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 37 increasing their positions, 25 reducing their positions, and 16 closing their positions.
133% more call options, than puts
Call options by funds: $1.83M | Put options by funds: $789K
48% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 25
13% more capital invested
Capital invested by funds: $793M → $900M (+$107M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5.06% less ownership
Funds ownership: 86.61% → 81.55% (-5.1%)
6% less funds holding
Funds holding: 98 → 92 (-6)
38% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$3.89M |
| 2 |
3C
361 Capital
Denver,
Colorado
|
+$2.61M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.54M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.51M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WIM
Woodford Investment Management
London,
United Kingdom
|
-$16.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12.4M |
| 3 |
Parallax Volatility Advisers
San Francisco,
California
|
-$5.53M |
| 4 |
JG
Jefferies Group
New York
|
-$5.02M |
| 5 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
-$4.33M |
TBPH Hedge Fund Activity: Q3 2019 in Review
92 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q3 2019, worth a combined $900M — up 13% from $793M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of TBPH and 10 opened new positions — a net loss of 6 holders — while 25 trimmed existing stakes and 37 added.
The largest buyer was UBS Group, adding an estimated $3.89M. The largest seller was Woodford Investment Management, cutting an estimated $16.4M.
- 92 institutional investors held Theravance Biopharma (TBPH) as of Q3 2019, down from 98 in Q2 2019.
- Funds reported $900M of Theravance Biopharma stock for Q3 2019, up 13% quarter-over-quarter.
- 10 funds opened new Theravance Biopharma positions in Q3 2019 and 16 closed out, a net change of -6 holders.
- The largest Theravance Biopharma buyer in Q3 2019 was UBS Group, an estimated $3.89M added.
- The largest Theravance Biopharma seller in Q3 2019 was Woodford Investment Management, an estimated $16.4M sold.
Based on aggregated 13F filings for Q3 2019.